Compare · LBPH vs NVS
LBPH vs NVS
Side-by-side comparison of Longboard Pharmaceuticals Inc. (LBPH) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBPH and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $274.13B, about 3809.4x LBPH ($72.0M).
- NVS has more recent analyst coverage (25 ratings vs 7 for LBPH).
- Company
- Longboard Pharmaceuticals Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $72.0M
- $274.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 25
Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest LBPH
- Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
- Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director
- SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.
- SEC Form POSASR filed by Longboard Pharmaceuticals Inc.
- SEC Form RW WD filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form EFFECT filed by Longboard Pharmaceuticals Inc.
- SEC Form 4 filed by Director Lynch Casey
- SEC Form 4 filed by Director Le Goff Corinne
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG